Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ARAF | P10398 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31749059 | 1.00 | NPFFR2 (0.44) | NPFFR2ADRB2ADRB1KIF11KDR | |
| SCHEMBL3306839 | 0.84 | TTR (0.47) | ADRB2ADRB1KDRHSD11B1PDK1 | |
| SCHEMBL5165740 | 0.84 | ADRB2 (0.41) | NPFFR2ADRB2ADRB1KDRHSD11B1 | |
| SCHEMBL12433188 | 0.83 | ADRB2 (0.45) | NPFFR2ADRB2ADRB1KDRHSD11B1 | |
| SCHEMBL28644289 | 0.83 | ADRB2 (0.40) | NPFFR2ADRB2ADRB1KDRHSD11B1 | |
| Hydrochloric Acid SCHEMBL7280694 | 0.83 | TTR (0.46) | ADRB2ADRB1KDRHSD11B1PDK1 | |
| SCHEMBL15358059 | 0.82 | NOTUM (0.49) | ADRB2ADRB1KDRPDK1 | |
| SCHEMBL2866567 | 0.81 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL13125475 | 0.81 | NPFFR2 (0.42) | NPFFR2KIF11KDRDHODHHTR2A | |
| SCHEMBL20702553 | 0.81 | KIF11 (0.49) | NPFFR2KIF11HTR2AHTR2CHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| US-9365612-B2 | Caspase inhibitors | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-06-14 | — | — | US | disclosed |
| EP-1439164-B1 | NOVEL PHENYLETHANOLAMINE COMPOUNDS HAVING BETA2-ACCEPTOR EXCITATORY FUNCTION AND THEIR PREPARATION METHOD | UNIV SHENYANG PHARMACEUTICAL (CN) | 2007-04-11 | — | — | EP | disclosed |
| US-7098364-B2 | Phenylethanolamine compounds as β2-receptor agonists, and methods of use and preparation thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2006-08-29 | — | — | US | disclosed |
| US-20040266867-A1 | Novel phenylethanolamine compounds having &bgr;<sb>2</sb>acceptor excitatory function and their preparation method | JINZHOU JIUTAI PHARMACEUTICAL CO., LTD. CHINA (CN) | 2004-12-30 | — | — | US | disclosed |
| EP-1439164-A1 | NOVEL PHENYLETHANOLAMINE COMPOUNDS HAVING BETA2-ACCEPTOR EXCITATORY FUNCTION AND THEIR PREPARATION METHOD | Shenyang Pharmaceutical University (CN) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | SLC5A2, SLC5A1, SLC2A2 | NPFFR2 782/4885ADRB2 229/4885ADRB1 387/4885 |
| US-20040266867-A1 | Novel phenylethanolamine compounds having &bgr;<sb>2</sb>acceptor excitatory function and their preparation method | ADRB2, ADRB3, CHRM3 | NPFFR2 170/4885ADRB2 1/4885ADRB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.